<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/24/lannett-nyselci-rating-lowered-to-sell-at-zacks-investment-research.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-24T01:54:46+00:00"/>
    <meta property="og:title" content="Lannett (NYSE:LCI) Rating Lowered to Sell at Zacks Investment Research"/>
    <meta property="og:description" content="Zacks Investment Research downgraded shares of Lannett (NYSE:LCI) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning, Zacks.com reports. According to Zacks, “Lannett Company manufactures and distributes high quality affordable generic medications that are the therapeutic equivalent of the brand-name pharmaceuticals. Their portfolio consists of numerous […]"/>
  </head>
  <body>
    <article>
      <h1>Lannett (NYSE:LCI) Rating Lowered to Sell at Zacks Investment Research</h1>
      <address><time datetime="2019-11-24T01:54:46+00:00">24 Nov 2019, 01:54</time> by <a rel="author" href="https://www.thecerbatgem.com/author/doug" target="_blank">Doug Wharley</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/lannett-company-inc-logo.jpg"/>
      </figure>
      <p><a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> downgraded shares of Lannett (NYSE:LCI) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning, <a href="https://www.zacks.com//">Zacks.com</a> reports.</p>
      <p>According to Zacks, “Lannett Company manufactures and distributes high quality affordable generic medications that are the therapeutic equivalent of the brand-name pharmaceuticals. Their portfolio consists of numerous products across a wide range of therapeutic areas. Lannett believes that their ability to select viable products for development, efficiently develop such products, including obtaining any applicable regulatory approvals, vertically integrate themselves into certain specialty markets and achieve economies in production are all critical for their success in the generic pharmaceutical industry in which they operate. Lannett Company, Inc., continues to dedicate significant capital toward developing new products as they believe their success is linked to their ability to continually introduce new generic products into the marketplace. “</p>
      <p>A number of other brokerages have also issued reports on LCI. Roth Capital reiterated a neutral rating on shares of Lannett in a research report on Wednesday, August 28th. SunTrust Banks increased their target price on Lannett from $10.00 to $14.00 and gave the company a hold rating in a research report on Wednesday, September 18th. Finally, <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=LCI">ValuEngine</a> upgraded Lannett from a sell rating to a hold rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating and four have issued a hold rating to the stock. The company presently has a consensus rating of Hold and an average target price of $11.63.</p>
      <p>Shares of <a href="https://www.marketbeat.com/stocks/NYSE/LCI/price-target/">NYSE:LCI</a> opened at $8.55 on Wednesday. Lannett has a 1 year low of $4.33 and a 1 year high of $15.52. The firm has a market capitalization of $356.57 million, a price-to-earnings ratio of 3.64 and a beta of 2.22. The company has a debt-to-equity ratio of 2.07, a current ratio of 2.43 and a quick ratio of 1.60. The business’s 50 day moving average price is $11.01 and its 200-day moving average price is $8.41.</p>
      <p>Lannett (NYSE:LCI) last announced its earnings results on Wednesday, November 6th. The company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.19 by $0.03. Lannett had a return on equity of 25.40% and a net margin of 0.52%. The firm had revenue of $127.30 million for the quarter, compared to analyst estimates of $120.78 million. During the same quarter last year, the firm posted $0.44 EPS. The business’s revenue was down 17.9% on a year-over-year basis. On average, sell-side analysts expect that Lannett will post 1.19 earnings per share for the current year.</p>
      <p>In other Lannett news, Director Albert Paonessa III sold 11,582 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $10.30, for a total value of $119,294.60. Following the transaction, the director now owns 62,140 shares in the company, valued at approximately $640,042. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at <a href="https://www.sec.gov/Archives/edgar/data/57725/000120919119048737/xslF345X03/doc4.xml">the SEC website</a>. Also, Director Patrick G. Lepore acquired 25,000 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was purchased at an average price of $9.82 per share, for a total transaction of $245,500.00. Following the acquisition, the director now directly owns 201,340 shares in the company, valued at approximately $1,977,158.80. The disclosure for this purchase can be found <a href="https://www.sec.gov/Archives/edgar/data/57725/000120919119048496/xslF345X03/doc4.xml">here</a>. Insiders acquired a total of 29,000 shares of company stock worth $280,380 in the last 90 days. 12.57% of the stock is currently owned by insiders.</p>
      <p>A number of hedge funds have recently made changes to their positions in the business. BlackRock Inc. lifted its holdings in Lannett by 4.6% in the 2nd quarter. BlackRock Inc. now owns 5,020,124 shares of the company’s stock valued at $30,421,000 after purchasing an additional 218,778 shares in the last quarter. D. E. Shaw &amp; Co. Inc. lifted its holdings in Lannett by 10.9% in the 2nd quarter. D. E. Shaw &amp; Co. Inc. now owns 3,451,212 shares of the company’s stock valued at $20,914,000 after purchasing an additional 339,593 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Lannett by 33.7% in the 2nd quarter. Vanguard Group Inc. now owns 2,689,687 shares of the company’s stock valued at $16,300,000 after purchasing an additional 678,248 shares in the last quarter. Morgan Stanley lifted its holdings in Lannett by 19.0% in the 2nd quarter. Morgan Stanley now owns 859,597 shares of the company’s stock valued at $5,210,000 after purchasing an additional 137,101 shares in the last quarter. Finally, Prudential Financial Inc. lifted its holdings in Lannett by 5.5% in the 2nd quarter. Prudential Financial Inc. now owns 726,803 shares of the company’s stock valued at $4,404,000 after purchasing an additional 37,850 shares in the last quarter. Institutional investors own 97.00% of the company’s stock.</p>
      <p>
        <b>About Lannett</b>
      </p>
      <p>Lannett Company, Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, suspension, soft gel, and injectable dosages.</p>
      <p>Featured Article: <a href="https://www.marketbeat.com/financial-terms/what-are-faang-stocks/">FAANG Stocks</a></p>
      <p>
        <a href="https://www.zacks.com/registration/pfp/?ALERT=ZER_LINK&amp;ADID=AMERBMN_CONTENT_ZER&amp;skip_rpt_name_check=skip_rpt_name_check&amp;t=LCI">Get a free copy of the Zacks research report on Lannett (LCI)</a>
      </p>
      <p>For more information about research offerings from Zacks Investment Research, visit <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks.com</a></p>
    </article>
  </body>
</html>